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Abstract
Introduction: Chronic constipation is a common condition that is difficult to treat. Existing options for the treatment of patients with 
different subgroups of constipation are limited. A new efficacious and safe drug is needed to limit the frequently observed adverse effects 
induced by laxatives, to improve general wellbeing and quality of life, and to provide an alternative for enemas or even resectional surgery 
in patients in whom stimulant laxatives cause disabling adverse effects or fail to increase bowel movement frequency.
Aims: The purpose of this article is to assess the current evidence supporting the use of the selective and high affinity serotonin-4 (5-HT4) 
receptor agonist prucalopride in the management of chronic constipation.
Evidence review: There are now convincing data from phase II and multicenter phase III randomized, double-blind, placebo-controlled 
trials that prucalopride treatment results in a clinically meaningful increase in the number of spontaneous complete bowel movements, a 
reduction of perceived severity of symptoms and improved disease-related quality of life in a significant proportion of patients. There is 
a rapid onset of the effect and the improvement is maintained for at least 12 weeks.
Prucalopride in a dose of up to 4 mg per day appeared generally well tolerated and devoid of serious cardiac events. Adverse events, 
most frequently headache and nausea, are usually mild or moderate and occur mainly during the first days of treatment. Prucalopride 
should be used with prudence and with careful assessment of the benefit-risk ratio until more clinical and electrophysiologic data become 
available, because relatively few patients have been exposed to the drug for long periods of time.
Place in therapy: Prucalopride 1–2 mg once daily may be given to patients suffering from chronic constipation for whom laxatives do 
not provide adequate relief of their symptoms. Patients with severe constipation and slow transit, who frequently develop tolerance to 
stimulant laxatives, are also eligible for prucalopride treatment.
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Core evidence place in therapy summary for prucalopride in chronic constipation
Outcome measure Evidence Implications
Patient-oriented evidence
Statistically significant percentage of patients with increase 
of ≥1 spontaneous complete bowel movement
Clear Improved symptom control and less need for laxatives
Percentage of patients with ≥3 spontaneous complete bowel 
movements and relief of constipation
Substantial Prucalopride can restore normal bowel function in a subgroup of difficult 
to treat patients
Improvement of perceived severity of constipation and of 
constipation-related symptoms
Clear Improved symptom control
Maintenance of clinical response Moderate Prucalopride may be used long term
Significant improvement of disease-specific quality of life Moderate Prucalopride can be considered as first-line treatment in patients in 
whom laxatives fail
Overall treatment satisfaction Moderate Prucalopride can be used as first-line treatment in patients in whom 
laxatives fail
Reduced need for laxatives Limited Additional laxatives may be required in patients with more  
severe symptoms
Efficacy superior to laxatives No evidence No controlled comparative trials are available
Efficacy in patients with associated pelvic floor dysfunction Limited Addition of prucalopride to current standard treatment may be useful
continued overleaf...Prucalopride | place in therapy
Scope, aims, and objectives
Although  the  pathogenesis  of  both  normal  and  slow  transit 
constipation  is  incompletely  understood,  there  is  plenty  of 
evidence  to  develop  serotonin-4  (5-HT4)  receptor  agonists  in 
the treatment of chronic constipation as they accelerate transit, 
increase stool frequency, and improve stool consistency (Cash 
& Chey 2005).
Prucalopride  (Resolor®,  Movetis)  is  a  selective  high  affinity 
5-HT4 receptor agonist that facilitates cholinergic and excitatory 
nonadrenergic, noncholinergic neurotransmission (Leclere 2005). 
The drug is orally active and acts via a systemic mechanism 
initiating high amplitude propagated contractions (HAPCs) in the 
colon (De Schryver et al. 2002). It enhances colonic propulsion 
and  accelerates  right  colon  emptying  (Emmanuel  et  al.  1998; 
Bouras  et  al.  2001).  Prucalopride  also  accelerates  gastric 
emptying and small bowel transit (Bouras et al. 2001). This review 
seeks to assess the scientific rationale for using prucalopride in 
chronic constipation and to discuss the current evidence for its 
role in the management of chronic constipation.
Methods
English language literature searches were conducted on June 26, 
2008 in the following databases, searching from the beginning of 
the database to date. The search terms used were “prucalopride”, 
“prucalopride UEGW” or “prucalopride and constipation”. The 
search strategy further included the limits “human, clinical trials, 
meta-analysis,  randomized  controlled  trial”,  “clinical  trial”,  or 
“meeting abstracts”.
•   PubMed, http://www.ncbi.nlm.nih.gov/entrez/queary.fcgi, 1966 
to date
•   EMBASE, http://www.datastarweb.com
•   National  Institute  for  Health  and  Clinical  Excellence  (NICE), 
http://www.nice.org.uk
•   York  University  Centre  for  Reviews  and  Dissemination 
databases, http://www.crd.york.ac.uk/crdweb/
•   Google, www.google.be
Following  removal  of  duplicates,  reviews  of  drug  class, 
treatment  options,  mechanistic  studies  in  healthy  volunteers, 
and  pharmacokinetic  studies,  a  total  of  six  full  papers  and   
11 abstracts were included in the evidence base. A summary of 
the literature search is presented in Table 1.
Disease overview
Constipation  is  a  frequent  gastrointestinal  motility  disorder   
with  a  prevalence  ranging  from  3%  to  28%  (Drossman   
et al. 1993; Talley et al. 1993; Higgins & Johanson 2004), and 
affecting  mainly  women  (Johanson  1998).  In  daily  practice 
constipation  is  defined  on  the  basis  of  a  combination  of   
symptoms including <2 bowel movements per week, hard stools, 
straining,  false  urge,  and  the  feeling  of  incomplete  emptying. 
The  symptom  constellation  and  underlying  pathophysiologic 
mechanisms may vary considerably among patients (Lembo & 
Camilleri 2003). Chronic constipation negatively affects health-
related quality of life and overall wellbeing, and generates high 
direct and indirect costs (Sonnenberg & Koch 1989; Rantis et 
al. 1997; Martin et al. 2006). It interferes with many aspects of 
patients’  lives,  including  normal  work,  and  is  associated  with 
psychologic morbidity (Damon et al. 2004; Dennison et al. 2005; 
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...table continued
Outcome measure Evidence Implications
Avoiding enemas or resectional surgery No evidence Controlled trials in the subgroup of patients with most severe signs and 
symptoms are awaited
Absence of severe and cardiovascular adverse effects Moderate A potential advance in the therapy of a population in need of a safe 
treatment providing adequate relief
Mild adverse effect profile Clear Prucalopride can be used as first-line treatment and patients with a 
good response are likely to benefit in the long term
Disease-oriented evidence
Significant shortening of the time to first stool Clear This finding may be in favor of pulse treatment, side effect  
profile permitting
Significant increase in bowel movements with no straining Clear Better symptom control and fewer laxative-induced side effects
Significant increase in bowel movements with  
normal consistency
Clear Better symptom control and fewer laxative-induced side effects
Significant dose-dependent effect Clear Dose reduction for adverse events does not necessarily compromise 
relief of constipation
Significant reduction in total colon transit time in patients 
with severe constipation
Limited Patients with more severe symptoms may require combination therapy 
with laxatives
Significant reduction in oro-cecal transit time and right 
colonic emptying
Clear Prucalopride may also be useful in patients with constipation and 
associated upper gastrointestinal motility disorders
Economic evidence
Cost effectiveness compared with stimulant or other 
laxatives and pelvic floor retraining
No evidence Long-term pharmacoeconomic studies need to be designedPrucalopride | place in therapy
Legoretta et al. 2006). In most patients with chronic constipation 
no obvious dietary or structural causes for their symptoms can 
be demonstrated.
Chronic  idiopathic  constipation  includes  normal  transit 
constipation,  slow  transit  constipation,  and  rectal  emptying 
disturbances  with  a  significant  overlap  among  the  subgroups 
(Velio & Bassotti 1996; Mertz et al. 1999; Locke et al. 2000). They 
generate symptoms that are nonspecific.
Patients  with  normal  transit  constipation  report  constipation   
and  associated  symptoms  of  abdominal  pain,  bloating,  or 
straining  in  the  presence  of  uncoordinated  contractions  in 
the left colon with stool traversing the colon at a normal rate. 
They  often  fulfil  the  criteria  of  irritable  bowel  syndrome  (IBS) 
(Crowell 2001). Patients with slow transit constipation have more   
severe  complaints  in  the  presence  of  delayed  transit  through   
the transverse colon that is accompanied by motility disturbances 
such as reduced HAPCs and the absence of early postprandial 
contractions (Bassotti et al. 1988; Bazzocchi et al. 1990). The 
etiology of these motility abnormalities is unclear. Occasionally, 
patients with more severe constipation also have a generalized 
gastrointestinal  motility  disorder  (van  der  Sijp  et  al.  1993).   
Rarely,  slow  transit  constipation  is  associated  with  colonic   
inertia not responding to stimulant laxatives (Preston & Lennard-
Jones 1986).
Rectal emptying disturbances, including rectoanal dyssynergia 
and  pelvic  floor  dysfunction,  are  characterized  by  excessive 
straining,  feeling  of  incomplete  evacuation,  to  application  of 
perineal pressure to assist evacuation or digital evacuation of 
even soft stools (Lembo et al. 2003). 
Role of the neurotransmitter serotonin in the regulation of 
gut function and constipation
Serotonin  or  5-hydroxytryptamine  (5-HT)  is  a  neurotransmitter   
that plays an important role in a broad range of functions in the gut. 
Serotonin exerts its effect in the body through a series of receptor 
subtypes of which the 5-HT3 and 5-HT4 receptor subtypes are 
best known in gastrointestinal physiology and physiopathology 
(Gershon 2004).
Binding  of  serotonin  to  5-HT4  receptors  stimulates  peristalsis, 
modulates fluid content of the colonic content, and decreases 
visceral hypersensitivity (Crowell 2001; De Ponti 2004). Patients 
with  slow  transit  constipation  have  reduced  numbers  and 
function  of  colonic  enterochromografine  cells  with  decreased 
serotonin activity (El Salhy et al. 1999). It is postulated that this 
reduced serotonin activity may be associated with the motor and 
secretory abnormalities described in patients with slow transit 
constipation. These data make the 5-HT4 receptor an attractive 
mechanistic target for agents that may be useful in the treatment 
of constipation (Cash & Chey 2005; Gershon & Tack 2007).
Current therapy options
A variety of treatment options have been proposed for patients 
with  chronic  constipation,  including  nonpharmacologic  and 
pharmacologic interventions. However, data on the effectiveness 
of  conservative  nonpharmacologic  strategies  supported 
by  clinical  trials  are  limited  (Jones  et  al.  2002).  There  is  no 
evidence that increased exercise, fluid intake, and bowel habit 
training provide relief of all symptoms in patients with chronic 
constipation  (Müller-Lissner  et  al.  2005).  Another  conservative 
nonpharmacologic  treatment  option,  biofeedback  retraining  of 
the pelvic floor, has been proposed in well-selected patients with 
rectoanal dyssynergia. There are now four randomized controlled 
trials  (RCTs)  which  demonstrate  that  biofeedback  is  effective 
in  a  subgroup  of  patients  with  chronic  constipation  and  the 
treatment of choice for dyssynergic defecation (Chiarioni et al. 
2005, 2006; Heymen et al. 2007; Rao et al. 2007). Meta analysis 
of studies involving biofeedback compared with other treatments 
suggested that biofeedback conferred a six-fold increase in the 
odds of treatment success (Koh et al. 2008). However, additional 
well-designed  studies  are  also  needed  that  take  into  account 
quality of life and psychologic morbidity.
Resectional  surgery  (subtotal  colectomy  with  ileorectal 
anastomosis) carries the risk of incapacitating adverse effects 
and can only be considered in well-selected patients with slow 
transit constipation associated with colonic inertia not responding 
to stimulant laxatives and enemas (Coremans 1990; Pemberton 
et al. 1991).
Orally and rectally administered laxatives adapted to the individual 
patient are by far the most popular pharmacologic options for 
patients  with  chronic  constipation.  There  is  good  evidence 
to  support  the  use  of  osmotic  laxatives,  more  particularly 
polyethylene glycol (PEG) in patients with chronic constipation. 
In  contrast,  there  is  a  paucity  of  quality  data  for  stimulant 
laxatives and glycerol (Ramkumar & Rao 2005) and head-to-head 
comparison to PEG is not available. But although the benefit of 
stimulant laxatives has not been supported by comprehensive 
clinical investigations, clinical experience indicates that laxatives 
such as bisacodyl, senna, and glycerol, tailored to the individual 
patient, are generally effective. As a rule, stimulant laxatives are 
effective in patients with slow transit constipation (Müller-Lissner 
47 Core Evidence 2008;3(1)
Number of records
Category Full papers Abstracts
Initial search 73 13
records excluded 67 4
records included 6 9
Additional studies identified 0 2
Total records included 6 11
Level 1 clinical evidence 
(systematic review, meta analysis)
0 0
Level 2 clinical evidence (RCT) 6 11
Economic evidence 0 0
For definitions of levels of evidence, see inside back cover or Core Evidence website  
(http://www.coremedicalpublishing.com).
RCT, randomized controlled trial.
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et  al.  2005).  A  significant  proportion  of  patients  with  chronic 
constipation are dependent on laxatives to achieve satisfactory 
bowel functions. 
Osmotic laxatives such as nonabsorbed sugars, saline laxatives, 
and PEG increase intestinal water secretion. They may be used 
if fibre therapy fails. PEG was found to be more effective than 
lactulose (Ramkumar & Rao 2005). The evidence supporting the 
efficacy of lactulose is only moderate.
The  short-term  efficacy,  tolerance,  and  safety  of  the  class  of 
osmotic laxatives are best documented for PEG-based laxatives, 
which have been shown to increase stool frequency and improve 
stool  consistency  (Di  Palma  et  al.  2000;  Chaussade  &  Minic 
2003). Obvious limitations of PEG-based laxatives are that only a 
subgroup of patients with mild chronic constipation respond, lack 
of effectiveness in providing adequate relief of all symptoms, and 
that  they  cause  bloating,  flatulence,  and  abdominal  cramping 
eventually  necessitating  discontinuation  of  the  laxative.  There 
is now convincing evidence to support the efficacy and safety 
of PEG in the long term (6 months) in adult patients, including 
elderly patients with chronic constipation (Corazziari et al. 2000; 
Di Palma et al. 2007).
Stimulant laxatives, both the diphenylmethane and anthraquinone 
derivates, can be used on a regular basis when osmotic laxatives 
fail, but their long-term use may be limited by adverse effects, 
such as severe cramps, eventually necessitating discontinuation 
of the treatment (Shelton 1980). Tolerance to stimulant laxatives 
is rare and occurs mainly in the patients with more severe slow 
transit constipation. In contrast, the need to increase the dose 
over time is frequently observed (Bengtsson & Ohlsson 2004). 
There are, however, no convincing data from pathology studies, 
performed by using adequate techniques, to support the belief 
that anthraquinone-containing laxatives may induce damage to 
the colon and its nerve plexuses (Müller-Lissner et al. 2005).
Unmet needs
The treatment of patients with normal or delayed colonic transit 
or outlet obstruction to defecation is nowadays far from always 
successful. This is particularly the case in the group of patients 
with more severe slow transit constipation and in patients with 
neurologic  disorders  such  as  Parkinson’s  disease,  multiple 
sclerosis, and paraplegia. The main effect of laxatives is limited 
to emptying of the colon. Laxatives rarely provide adequate relief 
of all the complaints of the patient and frequently induce nausea, 
bloating,  flatulence,  distension,  abdominal  discomfort,  and 
cramping abdominal pain (Müller-Lissner et al. 2005; Di Palma 
et al. 2007).
Therefore,  there  is  an  urgent  need  for  more  effective,  better 
tolerated,  and  safe  treatments  that  normalize  bowel  function 
(Di  Palma  2005).  In  patients  with  impaired  colonic  propulsive 
motor  activity,  a  gastrointestinal  prokinetic  may  be  a  better 
therapeutic approach (Cash & Chey 2005). Also, in patients with 
other types of chronic constipation, including those associated 
with  dyssynergic  defecation  and  pelvic  floor  dysfunction,  it  is 
reasonable  to  expect  that  the  addition  of  a  promotility  agent 
to current standard treatment options may be useful. Patients 
with  dyssynergic  defecation  may  benefit  from  biofeedback, 
which produces greater reductions in symptoms, and the use of 
enemas and suppositories rather than continuous PEG. In most 
cases however, some form of laxative treatment will be required, 
particularly  in  patients  with  pelvic  floor  dyssynergia  and  slow 
transit constipation (Chiarioni & Salandini 2005; Chiarioni et al. 
2006). The observation that abnormal serotonin signalling and 
reuptake appears to play a central role in the symptoms of a 
subset of patients with chronic constipation provides a rationale 
for the use of targeted serotonergic agents for the treatment of 
chronic constipation (Cash & Chey 2005; De Maeyer et al. 2008). 
Tegaserod, a selective partial 5-HT4 agonist, and to a much lesser 
extent cisapride, a first-generation promotility agent, were shown 
to reduce the need for laxatives and provide relief from multiple 
symptoms of constipation. However, concern about safety due 
to cardiotoxicity resulted in withdrawal of both promotility agents 
after they were approved by the FDA (Locke et al. 2000; Altabas 
et  al.  2003;  Johanson  et  al.  2004;  Müller-Lissner  et  al.  2004; 
Thompson 2007).




An initial phase II trial comparing prucalopride with placebo dates 
back  to  1994  (Coremans  et  al.  2003).  This  pilot  study,  which   
included  mainly  female  patients  with  longstanding  chronic 
constipation not responding adequately to laxatives and referred to 
a single tertiary referral center in Belgium, yielded promising results. 
Fifty-three patients were randomized in this placebo-controlled, 
double-blind trial. It was demonstrated that prucalopride 4 mg once 
daily for 4 weeks was significantly more effective than placebo in 
reducing time to first stool (P=0.071), softening stools (P=0.036), 
and  decreasing  straining  (P=0.037).  Prucalopride  also  had  a 
positive effect on stool frequency, feeling of complete evacuation, 
and total gut transit time, but the differences were not statistically 
significant  compared  with  placebo.  Mean  spontaneous  stool 
frequency increased by 2.34 stools per week after prucalopride 
and by 1.48 stools per week after placebo, suggesting a strong 
placebo  effect.  The  mean  weekly  frequency  of  laxative  intake 
compared with the run-in period was reduced by 0.73±0.4 (mean± 
standard error of the mean) in the prucalopride group and by 
0.59±0.24 in the placebo group. The difference, however, was not 
significant. Relief of constipation was experienced by a greater 
proportion of patients in the prucalopride group (37%) than in the 
placebo group (19.2%), and again, although clinically meaningful, 
the  difference  was  statistically  not  significant.  Dose  reduction 
for  excessive  gastrointestinal  response  did  not  significantly 
influence stool frequency, stool consistency, degree of straining, 
or patients’ overall relief of constipation. Total gut transit time 
showed a decrease of 10.39 hours with prucalopride compared 
with an increase of 7.45 hours with placebo. However, intergroup 
difference  was  not  statistically  significant,  possibly  because 
the mean total gut transit time during run-in was longer in the 
prucalopride group compared with placebo.
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This  initial  experience  with  prucalopride  treatment  for  severe 
chronic constipation supported further phase II investigations of 
prucalopride regimens in different forms of chronic constipation. 
The efficacy was further confirmed in six other phase II trials 
involving patients with chronic idiopathic constipation and one 
pilot phase II dose-escalation study in patients with constipation 
due to spinal cord injury.
Emmanuel  et  al.  (2002)  reported  on  74  women  with  chronic 
constipation stratified into slow and normal transit groups. Each 
group was randomized to receive 1 mg prucalopride or placebo 
once daily for 4 weeks. In this single centre, double-blind, placebo-
controlled trial conducted in the UK, prucalopride, not placebo, 
not only increased spontaneous stool frequency (P=0.008) and 
reduced time to first stool (P<0.001), it also significantly improved 
disease-specific  quality  of  life.  Furthermore,  prucalopride 
significantly reduced oro-cecal transit time and increased rectal 
sensitivity  to  distension  compared  with  placebo.  Prucalopride 
also reduced the mean number of retained radioopaque markers 
in the colon compared with placebo, but only in the subgroup 
with slow transit (P=0.069). 
A  subsequent  phase  II  dose-finding  study  was  conducted  by 
Sloots et al. (2002) in the Netherlands, evaluating the effect of 
prucalopride in a short-term, double-blind, placebo-controlled, 
crossover  study.  Twenty-eight  patients  were  randomized  to 
receive prucalopride 1 or 2 mg once daily or placebo. Compared 
with  placebo,  prucalopride  1  mg  significantly  increased  the 
mean  number  of  complete  spontaneous  stools  and  all  bowel 
movements  per  week.  It  also  significantly  decreased  the 
percentage of bowel movements with hard stools and straining, 
and enhanced the urge to defecate. Significant changes in stool 
frequency, stool consistency, and need to strain were not seen 
with the 2 mg regimen. This may be explained by a relatively high 
frequency of bowel movements in this group of patients during 
placebo treatment. The effect of both 1 and 2 mg prucalopride on 
mean total colonic transit time was not different from the effect 
of placebo.
Another  phase  II  dose-finding  RCT  including  251  patients 
conducted by Otten et al. (1999) in the Netherlands, confirmed 
a  clear  dose-dependent  increase  (P=0.026)  in  the  number  of 
responders.  Patients  with  chronic  constipation  (defined  as 
having ≥2 of the following for ≥6 months: ≤2 spontaneous bowel 
movements per week, for ≥25% of the time, and/or hard stools, 
and/or straining, and/or a sense of incomplete evacuation) were 
randomized to prucalopride 0.5, 1, or 2 mg twice daily and treated 
for a 12-week period. Prucalopride 1 and 2 mg twice daily, but 
not 0.5 mg, significantly increased stool frequency (P<0.01) and 
significantly decreased severity of constipation (P<0.02). Clinical 
improvement  with  the  higher  doses  correlated  with  a  shorter 
transit time, with a significant time difference in the descending 
colon (P<0.05), and the effect was maintained after 12 weeks. 
Time to the first spontaneous stool also significantly decreased 
with a median time of 22.4 hours for placebo versus 3 hours for 
the group taking prucalopride 2 mg twice daily.
Similar  results  were  observed  by  Felt-Bersma  and  colleagues 
(1999) in a short-term, multicenter, phase II dose-finding study 
including  172  patients  with  chronic  constipation  also  defined 
according to the Thompson criteria. Prucalopride 0.5, 1, or 2 mg 
administered once daily proportionally increased stool frequency 
(P<0.05) and decreased the time to the first stool (P<0.001). For 
patient self-assessment of bowel habit, therapeutic efficacy after 
4 weeks of treatment with prucalopride 0.5–2 mg was apparent 
compared with placebo (P<0.05). Prucalopride also significantly 
decreased total gut transit time from 49 to 39 hours at 1 mg and 
from 63 to 54 hours at 2 mg versus placebo.
These encouraging results were largely confirmed by a further 
phase  II  dose-finding  study  (n=234)  with  once  daily  doses 
of  prucalopride  0.5–4  mg  in  the  US  (Miner  et  al.  1999).  After   
4 weeks there was a dose-dependent increase in the frequency of 
spontaneous complete bowel movements and in the percentage 
of  responders  defined  as  having  ≥3  bowel  movements  per 
week: 32% with 2 mg (P<0.05) and 54% with 4 mg (P<0.001) 
versus  13%  with  placebo.  There  was  also  a  significant   
beneficial dose-dependent effect on frequency of straining and 
stool consistency.
Subsequently,  Joslyn  et  al.  (2000)  performed  a  phase  II 
multicenter,  double-blind,  placebo-controlled,  dose-finding 
study  in  303  elderly  patients  (age  65  years  and  over)  with 
chronic  constipation,  defined  as  ≤2  spontaneous  complete 
bowel  movements  per  week.  Patients  were  randomized  to 
prucalopride 1, 2, or 4 mg once daily, or placebo for 4 weeks. 
They demonstrated that prucalopride increased the proportion 
of  patients  with  ≥3  spontaneous  complete  bowel  movements 
and  improved  constipated-related  symptoms  versus  placebo, 
but the differences were not statistically significant. There was a 
significant increase in the proportion of patients with an increase 
of ≥1 complete bowel movement per week and an increase in the 
average change in the number of complete bowel movements 
with prucalopride.
Prucalopride  in  a  dose  of  1  or  2  mg  appeared  also  to  have 
definitive  activity  in  patients  with  constipation  due  to  spinal 
cord injury. Krogh et al. (2002) described their experience with 
23 patients in a double-blind, placebo-controlled, pilot, phase II 
dose-escalation study of 4 weeks’ duration. Compared with run-
in, the main measures of constipation severity decreased with 
prucalopride 1 and 2 mg. There was also an increase in average 
weekly frequency of all bowel movements over 4 weeks within 
the 2 mg group. The observed patient-reported improved bowel 
habit  was  accompanied  by  a  significant  reduction  in  median 
colon transit time by 38.5 hours [95% confidence interval (CI): 
–80, –5] within the 2 mg group. 
Moulin et al. (2008) performed a phase II, multicenter, double-
blind,  placebo-controlled  study  to  evaluate  the  efficacy  and   
safety  of  prucalopride  in  180  patients  with  constipation 
secondary to chronic daily opioid use. Prucalopride treatment 
improved bowel function and there was a trend toward improved 
quality of life. Prucalopride was also safe and well tolerated in 
these patients.
Phase III trials
Two  large,  placebo-controlled,  multicenter  phase  III  trials  to 
assess the therapeutic potential of prucalopride in severe chronic 
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constipation  confirm  prucalopride’s  effectiveness  and  safety 
(Tack et al. 2007; Camilleri et al. 2008).
In the European multicenter, parallel-group, randomized, double-
blind trial, efficacy was analyzed for 713 patients (90.8% female). 
Patients with <2 spontaneous complete bowel movements per 
week with straining, or a sensation of incomplete evacuation, or 
with hard stools received oral doses of prucalopride 2 or 4 mg 
once daily or placebo for 12 weeks. Results were similar with 
both  doses,  which  were  significantly  different  from  placebo 
(P≤0.01) at the primary endpoint; the percentage of patients with 
≥3 spontaneous complete bowel movements per week averaged 
over 4 and 12 weeks were 10.4% and 9.6% for placebo, 23.7% 
and 19.5% for prucalopride 2 mg, and 26.6% and 23.6% for 
prucalopride 4 mg, respectively.
Furthermore,  the  percentage  of  patients  with  an  increase  of   
1 or more spontaneous complete bowel movements per week, 
percentage  of  bowel  movements  with  normal  consistency, 
percentage  of  bowel  movements  with  no  straining,  perceived 
severity  of  constipation,  and  overall  score  from  a  validated 
questionnaire  measuring  symptoms  of  constipation,  were 
significantly  improved  with  2  and  4  mg  prucalopride  versus 
placebo averaged over 4 and 12 weeks.
Another  placebo-controlled,  randomized,  parallel-group, 
phase  III,  12-week  trial  conducted  at  38  centers  in  the  US 
with  similar  primary  and  secondary  endpoints  also  showed 
significant effects (Camilleri et al. 2008). Efficacy was analyzed in   
620  patients  (87.9%  female)  with  ≤2  spontaneous  complete 
bowel movements per week. The responses to 2 and 4 mg doses 
were similar: 30.9% of those receiving 2 mg once per day of 
prucalopride and 28.4% of those receiving 4 mg once per day 
had  ≥3  spontaneous  complete  bowel  movements,  compared 
with 12.0% in the placebo group (P<0.001). Furthermore, over 
12 weeks 47.3% of the patients receiving prucalopride 2 mg 
once per day and 46.6% of those receiving 4 mg once per day 
had an increase in the number of spontaneous, complete bowel 
movements of ≥1 per week, on average, compared with 25.8% 
in the placebo group (P<0.001).
In  addition,  the  use  of  prucalopride  2  or  4  mg,  as  compared 
with  placebo,  significantly  reduced  the  use  of  bisacodyl 
tablets taken per week (P<0.001). The median time to the first 
spontaneous, complete bowel movement was also significantly 
shorter after prucalopride compared with placebo. Furthermore, 
the percentage of patients quite satisfied or extremely satisfied 
with treatment efficacy during the 12-week period among the 
prucalopride 2 and 4 mg dose groups was significantly higher 
than among the placebo group (33.3% and 37.7%, respectively 
versus 17%, P<0.001).
Van  Outryve  et  al.  (2008)  performed  an  open  label,  phase  III, 
multicenter, long-term follow-up study in patients with chronic 
constipation. Patients had received treatment with prucalopride 
2 or 4 mg for 4 or 12 weeks in a double-blind placebo-controlled 
study, and were allowed to continue treatment for 24 months. 
Prucalopride was safe and well tolerated in the long term, and 
patient satisfaction with bowel function was maintained during 
the entire treatment period (Van Outryve et al. 2008).
Mechanistic studies
Prucalopride is known to stimulate gastrointestinal enterokinetic 
activity  in  animals  in  both  in-vitro  and  in-vivo  studies  (Briejer 
et  al.  2001a,b).  It  has  also  enterokinetic  effects  in  healthy   
volunteers  (Emmanuel  et  al.  1998;  Bouras  et  al.  1999;  Poen   
et  al.  1999).  This  dose-dependent  effect,  characterized 
by  a  significant  increase  in  stool  frequency  and  decrease 
in  stool  consistency  with  a  higher  percentage  of  loose/
watery  stools,  is  accompanied  by  a  significant  shortening 
of  mean  colonic  transit  time  and  proximal  colonic 
emptying  with  prucalopride  in  doses  ranging  from   
0.5–4  mg  once  daily  (Bouras  et  al.  1999;  Poen  et  al.  1999). 
An  effect  of  prucalopride  in  doses  of  up  to  4  mg  on  gastric   
emptying  or  small  bowel  transit  could  not  be  demonstrated 
in  healthy  volunteers  (Bouras  et  al.  1999).  In  contrast,  a 
physiologic study including 40 patients with chronic functional 
constipation  and  no  evidence  of  a  rectal  evacuation  disorder 
not  only  demonstrated  that  prucalopride  in  a  dose  of  2  and   
4 mg accelerates overall colonic transit and ascending colonic 
emptying,  but  also  gastric  emptying  and  small  bowel  transit; 
the  effect  appeared  to  be  dose  dependent  (Bouras  et  al. 
2001).  The  results  of  this  mechanistic  study  in  patients  with 
idiopathic constipation further suggest the possible usefulness 
of prucalopride not only in patients with constipation but also in 
patients with an associated upper or generalized gastrointestinal 
motility disorder.
Tolerability and safety
Overall prucalopride in a dose of 1–4 mg once daily was well 
tolerated, with the frequency of adverse events tending to be dose 
dependent. Adverse events were mild or moderate in all reported 
phase II and phase III studies, and disappeared in most patients 
within  the  first  week  of  treatment.  They  included  headache 
and nausea, and, less frequently, an excessive gastrointestinal 
response with abdominal cramps, diarrhea, and flatulence (Felt-
Bersma et al. 1999; Joslyn et al. 2000; Emmanuel et al. 2002; 
Coremans et al. 2003; Tack et al. 2007).
Adverse  events  eventually  resulted  in  discontinuation  of 
prucalopride  because  of  complaints  that  persisted  after  dose 
reduction.  In  the  first  phase  II  trial  with  the  4  mg  regimen,   
adverse  events  were  mild  in  two-thirds  of  the  patients  and   
resulted in discontinuation of the prokinetic drug in three out   
of 37 (8.1%) (Coremans et al. 2003). In the subsequent phase II   
trial with the 1 mg regimen, three out of 37 (8.1%) prucalopride-
treated patients withdrew from treatment because of adverse 
events (Emmanuel et al. 2002). Overall, 77% of the prucalopride- 
and 60% of the placebo-treated patients reported one or more 
adverse events. The frequency of nausea, abdominal pain, and 
headache  occurred  at  a  similar  frequency  in  both  treatment   
groups, whilst diarrhea and flatulence were more common with 
prucalopride  1  mg  once  daily.  Severe  adverse  events  were 
reported  in  similar  proportions  (36%  for  prucalopride  versus 
34% for placebo).
In the dose-finding phase II study most adverse events were also 
mild or moderate in severity (Sloots et al. 2002). Headache, the Prucalopride | place in therapy
most frequent adverse event, was more frequently reported by 
patients receiving prucalopride. Three of the 16 patients (18.8%) 
in the 2 mg group withdrew from treatment because of adverse 
events, which were predominantly gastrointestinal in nature. In 
elderly patients prucalopride was generally well tolerated. The 
most common adverse events were abdominal pain, back pain, 
headache,  nausea,  and  diarrhea,  which  also  occurred  in  the 
placebo group. Krogh et al. (2002) reported moderate-to-severe 
adverse events in four out of 11 patients with constipation due 
to spinal cord injury receiving prucalopride 2 mg necessitating 
discontinuation of treatment in two patients (18.2%).
Clinically  relevant  changes  in  cardiovascular  or  laboratory 
parameters were reported in none of the patients treated with 
prucalopride. Also, the use of prucalopride for longer periods of 
time (up to 24 months) and in elderly patients did not result in 
clinically significant changes in laboratory values or vital signs, 
including cardiovascular parameters (Joslyn et al. 2000; Tack et 
al. 2007; Van Outryve et al. 2008). 
These  data  were  recently  confirmed  by  results  of  a  large   
12-week,  multicenter,  phase  III  trial  conducted  in  the  US 
(Camilleri et al. 2008). Nausea, vomiting, diarrhea, and headache 
were reported more frequently by patients receiving prucalopride   
2 and 4 mg than those receiving placebo. However, these adverse 
events were mild or moderate in severity and occurred primarily 
during  the  first  days  of  treatment.  Transient  serious  adverse 
events were reported by only 1.4% and 3.4% of the patients 
receiving prucalopride 2 and 4 mg, respectively. Incidences of 
adverse  cardiovascular  effects  were  similar  among  the  three 
treatment groups and there were no clinically relevant changes 
in  the  electrocardiographic  variables  including  corrected  QT   
(QTc F) interval.
Based  on  the  available  clinical  experience  prucalopride,  a 
prokinetic with functional overlap with the 5-HT4 receptor agonists 
cisapride and tegaserod (both of which have been withdrawn from 
the market due to adverse cardiac events), appears safe. The 
drug was not associated with adverse ventricular repolarization 
effects  or  associated  with  increased  ischemic  events  (Tack 
et  al.  2007;  Camilleri  et  al.  2008).  Electrophysiologic  studies 
with  prucalopride  on  ion-channel  currents  in  isolated  cardiac 
cells showed that the drug had a lower affinity for the cardiac 
potassium  HERG  channel  than  does  cisapride,  a  prokinetic 
that is associated with a risk of torsade de pointes arrhythmias 
due to excessive action potential prolongation through HERG-
channel inhibition. These studies seem to indicate that although 
prucalopride blocks HERG channels, a large safety margin at 
therapeutic concentrations exists (Chapman & Paternack 2007). 
Nevertheless, some safety concerns persist and additional data 
have been requested by some authors (Moss 2008). Taking into 
account  that  at  the  present  time  relatively  few  patients  have 
been exposed to prucalopride for longer periods of time, the 
low rate of occurrence of the life-threatening cardiac side effects 
related to prolongation of QTc and the lack of more complete 
electrophysiologic and pharmacologic data warrants a careful 
assessment of the long-term benefit-risk ratio when prescribing 
the  drug  in  an  individual  patient  with  chronic  constipation 
amenable to prokinetic drug treatment.
Economic evidence
There  are  no  published  data  on  the  assessment  of 
resource  utilization  with  prucalopride  treatment  or  studies 
providing  an  economic  evaluation  of  prucalopride  in  chronic   
functional constipation.
There appears to be less need for laxatives and thus less cost 
and adverse events that may interfere with the ability to work in 
patients successfully treated with prucalopride. However, there 
are as yet no studies that compare prucalopride and laxatives.
Dosage, administration, and formulations
Prucalopride is available in oral tablets of 0.5, 1, 2, and 4 mg. The 
performed trials provide valuable information on the frequency 
and  timing  of  prucalopride  dosing,  but  it  is  clear  that  their   
results  may  need  to  be  adapted  to  the  needs  of  individual   
patients. Once daily administration appears to be appropriate 
and  this  may  be  related  to  the  long  plasma  elimination  half-
life  of  prucalopride  of  approximately  24  hours  (Bouras  et  al. 
2001).  The  fast  mode  of  action  of  the  drug  with  a  maximum 
concentration  of  ~3  hours  (Bouras  et  al.  2001)  opens  up  the 
possibility  of  intermittent  treatment,  but  data  are  currently 
not  available.  The  effect  of  prucalopride  on  stool  frequency 
and  constipation-related  symptoms  is  clearly  dose  related. 
Prucalopride  2  mg  once  daily  appears  to  be  consistently 
equally as effective as 4 mg once daily in all published studies. 
The effect of 1 mg is less consistent and a dose regimen of   
0.5 mg once daily proved suboptimal in all studies.
Place in therapy
Chronic  constipation  is  a  common  motility  disorder  that  may 
affect overall wellbeing and quality of life. A subgroup of patients 
with chronic constipation not only has a delayed colonic transit 
but also a disordered transit through the upper gastrointestinal 
tract, associated with symptoms of dyspepsia. Another subgroup 
has symptoms related to impaired rectal emptying due to pelvic 
floor dysfunction or rectoanal dyssynergia.
The  majority  of  the  currently  available  treatments  for  chronic 
constipation are relatively ineffective, particularly for more severe 
cases,  and  have  not  been  tested  in  well-controlled  modern 
trials. Laxatives remain the most popular treatment for chronic 
constipation  although  systematic  reviews  of  these  agents  do 
not provide unequivocal evidence that they result in adequate 
relief of constipation. In daily practice they appear to be generally 
effective and safe, with no evidence of loss of effect with time 
in the majority of patients. Tolerance seems to occur mainly in 
patients with slow transit constipation in whom only stimulant 
laxatives are effective. A major limitation of chronic treatment with 
laxatives, however, is that although they increase stool frequency, 
they  do  not  relieve  all  the  constipation-associated  symptoms 
such as bloating, abdominal discomfort, and pain, resulting in 
poor compliance. They also may induce troublesome adverse 
events including flatulence, bloating, and abdominal cramping 
pain, in itself often associated with chronic constipation.
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Uncovering  the  role  of  5-HT4  receptors  in  the  gastrointestinal 
tract  and  the  development  of  selective  5-HT4  receptor 
agonists  that  have  clear-cut  prokinetic  activities  offered  great 
opportunities for the treatment of patients with different types 
of chronic constipation. Specific 5-HT agonists, in contrast to 
other available drugs that increase intestinal motor activity such 
as  metoclopramide  and  prostigmine  that  are  poorly  tolerated, 
are an innovative and successful new approach to the treatment   
of constipation.
Prucalopride is a selective high-affinity 5-HT4 receptor agonist that 
was developed for constipation, and based on available evidence 
and compared with its predecessors, cisapride and tegaserod, 
offers improved efficacy and safety to treat patients with severe 
chronic constipation. This potent, highly selective 5-HT4 agonist 
proved an efficacious, safe, and well-tolerated treatment for the 
multiple symptoms of chronic constipation. Prucalopride has a 
rapid onset of enterokinetic activity and increases the number 
of complete spontaneous bowel movements. Adequate relief of 
constipation  among  patients  with  severe  constipation  occurs 
significantly  more  frequently  in  patients  taking  prucalopride 
compared with placebo. It normalizes bowel function in about 
25% of treated patients and has a beneficial effect on associated 
symptoms such as hard stools, feeling of incomplete evacuation, 
and straining. Most importantly, it results in improved sense of 
general wellbeing and quality of life.
Prucalopride is well tolerated and remained effective in an RCT 
of up to 12 weeks’ duration. The most common adverse events 
of nausea and headache occurred in the first week of treatment 
in the majority of patients. Prucalopride also appears to be a safe 
drug and there is no evidence at the present time that it affects 
the electrocardiogram or prolongs QTc interval.
A single daily dose appears appropriate. The effects on stool 
frequency, constipation-associated symptoms as well as adverse 
effects are dose related. Prucalopride 2 mg once daily appears 
to be as effective as 4 mg once daily in clinical trials. The effect 
of 1 mg is less consistent and a dose regimen of 0.5 mg once 
daily  proved  suboptimal.  The  percentages  of  responders  to   
2 and 4 mg appear similar. A 2 mg dose regimen appears optimal 
to start, with dose escalation when needed and dose reduction in 
the case of adverse events consistent with the prokinetic action 
that would preclude further treatment with 2 mg once daily.
Prucalopride  significantly  increases  the  stool  frequency  in  a 
clinically significant percentage of patients, but the effect may 
remain  suboptimal  in  patients  with  more  severe  constipation. 
Prokinetic agents can then be used in combination with other 
available therapeutic options such as stimulant laxatives, which 
were used as escape medication in the RCT, or reeducation of the 
pelvic floor. Taking into account the rapid action of prucalopride, 
one could also use this colokinetic agent intermittently and not 
on a daily basis, side effects permitting. Patients with chronic 
constipation  associated  with  a  disordered  transit  through  the 
upper gut may also benefit from prucalopride as it accelerates not 
only total colonic transit and ascending colon emptying but also 
gastric emptying and small bowel transit. Patients with chronic 
constipation and pelvic floor disorders are traditionally excluded 
from trials with colokinetic agents to avoid potential error in the 
evaluation of the therapeutic potential of these agents in patients 
with chronic constipation that have no evidence of disordered 
rectal  emptying.  Taking  into  account  the  obvious  overlap  of 
different  subtypes  of  constipation,  one  may  speculate  that 
prucalopride, by accelerating oro-cecal and segmental colonic 
transit and improving stool consistency, may also contribute to 
better symptom control in patients with constipation and rectal 
evacuation disturbances. This is in accordance with the reported 
beneficial effect of prucalopride in patients with paraplegia.
Acknowledgements
Professor  Coremans  received  honoraria  from  Janssen 
Pharmaceutica  between  1999  and  2002  for  conducting  trials 
with  prucalopride.  He  served  on  advisory  boards  for  Janssen 
Pharmaceutica until 2002.
References
Altabas K, Bilic A, Juricic D, et al. The efficacy of cisapride vs placebo and diet 
in patient with chronic constipation. Coll Antropol. 2003;27:197–204.
Bassotti G, Gaburri M, Imbimbo B, et al. Colonic mass movements in idiopathic 
chronic constipation. Gut. 1988;29:1173–1179.
Bazzocchi G, Ellis J, Villanueva-Meyer J, et al. Postprandial colonic transit and 
motor activity in chronic constipation. Gastroenterology. 1990;98:686–693.
Bengtsson M, Ohlsson B. Retrospective study of long-term treatment with 
sodium picosulfate. Eur J Gastroenterol Hepatol. 2004;16:433–444.
Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic 
transit by the benzofuran 5-HT4 agonist, prucalopride in healthy humans. 
Gut.1999;44:482–486.
Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie G, Zinsmeister AR. 
Prucalopride accelerates gastrointestinal and colonic transit in patients with 
constipation. Gastroenterology. 2001;120:354–360.
Briejer MR, Bosmans JP, Van Daele P, et al. The in vitro pharmacological 
profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol. 
2001a;423:71–83.
Briejer MR, Prins NH, Schuurkes JA. Effects of the enterokinetic prucalopride 
(R093877) a colonic motility in the fasted dogs. Neurogastroenterol Motil. 
2001b;13:465–472.
Camilleri M, Kerstens R, Ryckx A, Vandeplassche L. A placebo-controlled trial 
of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:2344–
2354.
Cash BD, Chey WD. Review article: the role of serotonergic agents in the 
treatment of patients with primary chronic constipation. Aliment Pharmacol 
Ther. 2005;22:1047–1060.
Chapman H, Pasternack M. The action of the novel gastrointestinal prokinetic 
prucalopride on the HERG K+ channel and the common T897 polymorph. Eur J 
Pharmacol. 2007;554:98–105.
Chaussade S, Minic M. Comparison of efficacy and safety of two doses 
different polyethylene glycol-based laxatives in the treatment of constipation. 
Aliment Pharmacol Ther. 2003;17:165–172.
Chiarioni G, Salandini L, Whitehead WE. Biofeedback benefits only patients 
with outlet dysfunction, not patients with isolated slow transit constipation. 
Gastroenterology. 2005;129:86–97.
Chiarioni G, Whitehead WE, Pezza V, Morelli A, Bassotti G. Biofeedback 
is superior to laxatives for normal transit constipation due to pelvic floor 
dyssynergia. Gastroenterology. 2006;130:657–664.
Coremans GE. Surgical aspects of severe chronic non-Hirschsprung 
constipation. Hepatogastroenterology. 1990;37:588–595.
52Prucalopride | place in therapy
Core Evidence 2008;3(1) 53
Coremans G, Kerstens R, De Pauw M, Stevens M. Prucalopride is effective 
in patients with severe chronic constipation in whom laxatives fail to provide 
adequate relief. Results of a double-blind, placebo-controlled clinical trial. 
Digestion. 2003;67:82–89.
Corazziari E, Badiali D, Bazzocchi G, et al. Long term efficacy, safety, and 
tolerability of low daily doses of isosmotic polyethylene glycol electrolyte 
balanced solution (PMF-100) in the treatment of functional chronic 
constipation. Gut. 2000;46:522–526.
Crowell MD. The role of serotonin in the pathophysiology of irritable bowel 
syndrome. Am J Manag Care. 2001;7:S252–S260.
Damon H, Dumas P, Mion F. Impact of anal incontinence and chronic 
constipation on quality of life. Gastroenterol Clin Biol. 2004;28:16–20.
De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar 
but not the same. Neurogastroenterol Mol. 2008;20:99–112.
Dennisson C, Prasad M, Lloyd A, Bhattacharyya SK, Dhawan R, Coyne 
K. The health-related quality of life and economic burden of constipation. 
PharmacoEconomics. 2005;23:461–476.
De Ponti F. Pharmacology of serotonin: what a clinician should know. Gut. 
2004;53:1520–1535.
De Schryver AM, Andriesse GI, Samsom M, Smout AJ, Gooszen HG, 
Akkermans LM. The effects of the specific 5HT(4) receptor agonist, 
prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol 
Ther. 2002;16:603–612.
Di Palma JA, De Ridder PA, Orlando RC, Kolts BE, Cleveland MVB. A 
randomized placebo-controlled multicenter study of the safety and efficacy of 
a new polyethylene glycol laxative. Am J Gastroenterol. 2000;95:446–450.
Di Palma JA. Expert commentary – new developments in the treatment of 
constipation. Med Gen Med. 2005;7:17.
Di Palma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, 
multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic 
treatment of chronic constipation. Am J Gastroenterol. 2007;102:1436–1441.
Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional 
gastrointestinal disorders. Prevalence, sociodemography, and health impact. 
Dig Dis Sci. 1993;38:1569–1580.
El Salhy M, Norrgard O, Spinell S. Abnormal colonic endocrine cells in patients 
with chronic idiopathic slow transit constipation. Scand J Gastroenterol. 
1999;34:1007–1011.
Emmanuel AV, Kamm MA, Roy AJ, et al. Effect of a novel prokinetic drug 
RO93877 on gastrointestinal transit in healthy volunteers. Gut. 1998;42:511–
516.
Emmanuel AV, Roy AJ, Nicholls TJ, Kamm MA. Prucalopride, a systemic 
enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther. 
2002;16:1347–1356.
Felt-Bersma RJF, Bouchacha M, Wurzer H, Van Outryve M, Bosschert H, Van 
‘t Klooster G. Effects of a new enterokinetic drug, prucalopride, on symptoms 
of patients with chronic constipation. A double-blind, placebo-controlled, 
multicenter study in Europe. Gastroenterology. 1999;116:A992 (Abstract).
Gershon MD. Review article: serotonin receptors and transporters – roles 
in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther. 
2004;20(Suppl. 7):3–14.
Gershon MD, Tack J. The serotonin signalling system: from basic 
understanding to drug development for functional GI disorders. 
Gastroenterology. 2007;132:397–414.
Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman D, Whitehead WE. 
Randomized, controlled trial shows biofeedback to be superior to alternative 
treatments for patients with pelvic floor dyssynergia-type constipation. Dis 
Colon Rectum. 2007;50:428–441.
Higgins PD, Johanson JF. Epidermiology of constipation in North America: a 
systemic review. Am J Gastroenterol. 2004;99:750–759.
Jones MP, Talley NJ, Nuyts G, et al. Lack of objective evidence of efficacy of 
laxatives in chronic constipation. Dig Dis Sci. 2002;47:2222–2230.
Johanson JF. Geographic distribution of constipation in United States. Am J 
Gastroenterol. 1998;93:188–191.
Johanson JF, Wald A, Tougas G, et al. Effect of tegaserod in chronic 
constipation: randomized, double-blind controlled trial. Clin Gastroenterol 
Hepatol. 2004;2:796–805.
Joslyn A, Stevens M, De Pauw M, Kerstens R. Prucalopride is safe and 
generally well tolerated in elderly patients with chronic constipation. Am J 
Gastroenterol. 2000;95:2537–2538 (Abstract).
Koh CE, Young CJ, Young JM, Solomon MJ. Systematic review of randomized 
controlled trials of the effectiveness of biofeedback for pelvic floor dysfunction. 
Br J Surg. 2008;95:1079-1087.
Krogh K, Jensen MB, Gandrup P, et al. Efficacy and tolerability of prucalopride 
in patients with constipation due to spinal cord injury. Scand J Gastroenterol. 
2002;37:431–436.
Leclere PG, Prins HH, Schuurkes JAJ, Lefebvre RA. 5-HT4 receptors located 
on cholinergic nerves in human colon circular muscle. Neurogastroentero Motil. 
2005;17:366–375.
Legoretta A, Clark S, Marehbian J, et al. Symptoms associated with 
chronic gastrointestinal disorders interfere with daily living as assessed by 
patient reported outcomes in the primary care setting. Am J Gastroenterol. 
2006;101:S490 (Abstract).
Lembo A, Camilleri M. Chronic constipation. N Engl J Med. 2003;349:1360–
1368.
Locke GR 3rd, Pemberton JH, Phillips SF. AGA technical review on 
constipation. American Gastroenterological Association. Gastroenterology. 
2000;119:1766–1778.
Martin BC, Barghout V, Cerulli A. Direct medical costs of constipation in the 
United States. Managed Care Interface. 2006;16:43–39.
Mertz H, Naliboff B, Mayer E. Physiology of refractory chronic constipation. Am 
J Gastroenterol. 1999;94:609–615.
Miner PhB Jr, Nichols T Jr, Silvers DR, Joselyn A, Woods M. The efficacy and 
safety of prucalopride in patients with chronic constipation. Gastroenterology. 
1999;116:A-1043 (Abstract).
Moss AJ. The long and short of a constipation-reducing medication. N Engl J 
Med. 2008;358:2402–2403.
Moulin DE, Rykx A, Kerstens R, Vandeplassche L. Randomized, double-
blind placebo-controlled trial to evaluate efficacy and safety of prucalopride 
(Resolor®) in patients with opioid-induced constipation. Gastroenterology. 
2008;134:A-92 (Abstract).
Müller-Lissner S, Kamm M, Haeck P, et al. Long-term safety and tolerability of 
tegaserod in chronic constipation. Gastroenterology. 2004;126:A602 (Abstract). 
Müller-Lissner SA, Kamm M, Scarpignato C, Wald A. Myths and 
misconceptions about chronic constipation. J Gastroenterol. 2005;100:232–
242.
Otten MH, Schneider H, Wurzer H, et al. A double-blind, placebo-controlled 
evaluation of safety and efficacy of 12-weeks, twice-daily treatment with 
prucalopride in patients with chronic constipation. Gastroenterology. 
1999;116:A1055 (Abstract).
Pemberton JH, Roth DM, Ilstrup DM. Evaluation and surgical treatment of 
severe chronic constipation. Ann Surg. 1991;214:403–411.
Poen AC, Felt-Bersma RJF, Van Dongen PAM, Meuwissen SGM. Effect 
of prucalopride, a new enterokinetic agent, on gastrointestinal transit 
and anorectal function in healthy volunteers. Aliment Pharmacol Ther. 
1999;13:1493–1497.
Preston DM, Lennard-Jones JE. Severe chronic constipation of young women: 
idiopathic slow transit constipation. Gut. 1986;27:41–48.
Ramkumar D, Rao SSC. Efficacy and safety of traditional medical therapies for 
chronic constipation: systemic review. Am J Gastroenterol. 2005;100:936–971.
Rantis PC Jr, Vernava AM 3rd, Daniel GL, Longo WE. Chronic constipation – is 
the work-up worth the cost? Dis Colon Rectum. 1997;40:280–286.
Rao SS, Seaton K, Miller M, et al. Randomized controlled trial of biofeedback, 
sham feedback, and standard therapy for dyssynergic defection. Clin 
Gastroenterol Hepatol. 2007;5:331–338.
Shelton MG. Standardized senna in the management of constipation in the 
puerperium. A clinical trial. S Afr Med J. 1980;57:78–80. Prucalopride | place in therapy
54
© 2008 Core Medical Publishing Limited
Sloots CE, Poen AC, Kerstens R, et al. Effects of prucalopride on colonic 
transit, anorectal function and bowel habits in patients with chronic 
constipation. Aliment Pharmacol Ther. 2002;16:759–767.
Sonnenberg A, Koch TR. Physician visits in the United States for constipation: 
1958–1986. Dig Dis Sci. 1989;34:601–611.
Tack J, Tan G, Vandeplassche L. A randomized, double-blind, placebo-
controlled trial to evaluate efficacy and safety of prucalopride in patients with 
chronic constipation. Gut. 2007;56:A46 (Abstract). 
Talley NJ, Weaver AL, Zinsmeister AR, Melton L. Functional constipation and 
outlet delay: a population-based study. Gastroenterology. 1993;105:781–790.
Thompson CA. Novartis suspends tegaserod sales at FDA’s request. Am J 
Health Syst Pharm. 2007;64:1020.
van der Sijp JRM, Kamm MA, Nightingale JMD, et al. Disturbed gastric and 
small bowel transit in severe idiopathic constipation. Dig Dis Sci. 1993;38:837–
844.
Van Outryve MJ, Beyens G, Kerstens R, Vandeplassche L. Long-term follow-up 
study of oral prucalopride (Resolor®) administered to patients with chronic 
constipation. Gastroenterology. 2008;134:A-547(T1400).
Velio P, Bassotti G. Chronic idiopathic constipation: pathophysiology and 
treatment. J. Clin Gastroenterol. 1996;22:190–196.
Correspondence:  Professor  Georges  Coremans,  Division  of 
Gastroenterology,  University  Hospital  Gasthuisberg,  University 
of  Leuven,  Herestraat  49,  B-3000  Leuven,  Belgium  or  at   
georges.coremans@uz.kuleuven.ac.be 